SCHEMBL7526110

SCHEMBL7526110

Oc1cccc2c1SCCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.48
BAD Q92934 1/20 0.48
HTR1A P08908 2/20 0.41
ADRA2A P08913 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
TSHR P16473 2/20 0.36
ALDH1A1 P00352 3/20 0.34
ALOX15 P16050 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
HPN P05981 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALOX5 P09917 1/20 0.34
THRB P10828 1/20 0.34
PTGS1 P23219 1/20 0.34
PDE4A P27815 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10816016 0.88 BCL2L1 (0.42) BCL2L1BADHTR1AADRA2ASLC6A2
SCHEMBL23979971 0.76 HTR1A (0.38) BCL2L1BADHTR1AADRA2ASLC6A2
SCHEMBL8901220 0.76 ADRA2A (0.38) BCL2L1BADHTR1AADRA2ASLC6A2
SCHEMBL8581327 0.76 HTR1A (0.41) BCL2L1BADHTR1AADRA2ASLC6A2
SCHEMBL23987301 0.76 HTR1A (0.39) BCL2L1BADHTR1AADRA2ASLC6A2
SCHEMBL4104527 0.76 HPGD (0.38) BCL2L1BADHTR1AADRA2ASLC6A2
SCHEMBL18297576 0.76 HTR1A (0.38) BCL2L1BADHTR1AADRA2ASLC6A2
SCHEMBL7426602 0.76 ALDH1A1 (0.40) BCL2L1BADHTR1AADRA2ASLC6A2
SCHEMBL9409715 0.76 HTR1A (0.41) BCL2L1BADHTR1AADRA2ASLC6A2
SCHEMBL17058346 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2701673-B1 DYE COMPOSITION USING A PARTICULAR PHENOLIC COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESSES AND DEVICES L'ORÉAL (FR) 2017-09-13 EP disclosed
US-9241886-B2 Dye composition using a particular phenolic coupler in a medium rich in fatty substances, processes and devices L'OREAL (FR) 2016-01-26 US disclosed
US-9241886-B2 Dye composition using a particular phenolic coupler in a medium rich in fatty substances, processes and devices L'OREAL (FR) 2016-01-26 US disclosed
US-20140053346-A1 DYE COMPOSITION USING A PARTICULAR PHENOLIC COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESSES AND DEVICES L'OREAL (FR) 2014-02-27 US disclosed
US-20140053346-A1 DYE COMPOSITION USING A PARTICULAR PHENOLIC COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESSES AND DEVICES L'OREAL (FR) 2014-02-27 US disclosed
EP-0873993-B1 Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2002-02-20 EP disclosed
US-5919814-A Heterocyclic compounds ADIR ET COMPAGNIE (FR) 1999-07-06 US disclosed
EP-0671397-B1 Alkylaminoindane compounds, processes for their preparation and pharmaceutical compositions containing them ADIR (FR) 1999-02-03 EP disclosed
EP-0873993-A1 Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1998-10-28 EP disclosed
US-5569669-A Alkylaminoindane compounds ADIR ET COMPAGNIE (FR) 1996-10-29 US disclosed
EP-0671397-A1 Alkylaminoindanes compounds, processes for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1995-09-13 EP disclosed
EP-0571243-B1 Thiochromane derivatives, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1995-07-26 EP disclosed
US-5389668-A Thiochroman compounds ADIR ET COMPAGNIE (FR) 1995-02-14 US disclosed
US-5385930-A Treating central nervous system disorders like anxiety and depression ADIR ET COMPAGNIE (FR) 1995-01-31 US disclosed
US-5371103-A Thiochroman compounds ADIR ET COMPAGNIE (FR) 1994-12-06 US disclosed
US-5332741-A Antidepressants ADIR ET COMPAGNIE (FR) 1994-07-26 US disclosed
EP-0571243-A1 Thiochromane derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1993-11-24 EP disclosed
US-5254595-A Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them ELF SANOFI (FR) 1993-10-19 US disclosed
EP-0375560-B1 ARYLOXYPROPANOLAMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME ELF SANOFI (FR) 1993-05-12 EP disclosed
EP-0375560-A1 Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same ELF SANOFI (FR) 1990-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140053346-A1 DYE COMPOSITION USING A PARTICULAR PHENOLIC COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESSES AND DEVICES C1R, F12, AKR1C3 BCL2L1 2049/4885BAD 3340/4885HTR1A 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.